checkAd

     232  0 Kommentare Navidea Biopharmaceuticals Announces SNMMI Press Release and Recognition of Phase 1/2 Study Results

    Navidea Biopharmaceuticals, Inc. (NYSE American:NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce that the results of the Company’s NAV3-21 clinical study at the Society of Nuclear Medicine and Molecular Imaging (“SNMMI”) Annual Meeting in Anaheim, CA have been highlighted with a press release by the SNMMI (http://www.snmmi.org/NewsPublications/NewsDetail.aspx?ItemNumber=31987). The presentation, titled “A Phase I/Phase II Study of Intravenously (“IV”) Administered Tc99m Tilmanocept (“TCT”) to Determine Safety, Tolerability, Optimal Clinical Dose Selection, and Imaging Timepoint in Patients Clinically Diagnosed with Rheumatoid Arthritis (“RA”)" was delivered at the Society’s Annual Meeting on Sunday, June 23, 2019 by Arash Kardan, M.D. In addition, an abstract of the presentation will be published in a future edition of the Journal of Nuclear Medicine.

    The NAV3-21 study enrolled subjects with active, moderate-to-severe RA, and healthy controls. Results from the completed trial demonstrate that Tc99m tilmanocept is well-tolerated with no serious adverse events, adverse drug reactions, or drug-related adverse events observed. Additionally, static planar images revealed joint-specific Tc99m tilmanocept localization in RA subjects to disease-involved joints of the shoulders, knees, hands, and feet, but no joint-specific localization in healthy control subjects, revealing potentially significant immunodiagnostic information about CD206-expressing synovial macrophage involvement in RA. An optimal imaging time window post-Tc99m tilmanocept IV administration, as well as optimal dosing, were also determined.

    Michael Rosol, Chief Medical Officer for Navidea, said, “We are delighted by the recognition of the importance of our Phase 1/2 study results by the SNMMI. In this work we have shown that intravenous administration of Tc99m tilmanocept had no adverse safety signals and that it localizes specifically to joints of patients with active RA and not to those of healthy controls. These results were fundamental to moving forward with our planned Phase 2B and Phase 3 studies and our planned eventual submission to FDA for registration for indications in RA.” Dr. Rosol continued, “This press release and highlight by the SNMMI is the type of external validation of our work that reflects the great medical need for a robust, objective, noninvasive means of assessing inflammation in RA-involved joints. It is our expectation that Tc99m tilmanocept can address this need and provide critical information for rheumatologists to put their patients on the correct therapeutic pathway earlier than is currently possible.”

    Seite 1 von 3




    Business Wire (engl.)
    0 Follower
    Autor folgen

    Navidea Biopharmaceuticals Announces SNMMI Press Release and Recognition of Phase 1/2 Study Results Navidea Biopharmaceuticals, Inc. (NYSE American:NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce that the results of the Company’s NAV3-21 …